Sugi Predict

Sugi Predict / Compounds / SCHEMBL274798

SCHEMBL274798

SCHEMBL274798

CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(=O)(O)OCCN

nearest known ligand 0.72

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ P2RY10 O00398 12/20 0.72
▸ GPR174 Q9BXC1 9/20 0.72
▸ GPR34 Q9UPC5 6/20 0.72
▸ LPAR1 Q92633 6/20 0.70
▸ LPAR4 Q99677 3/20 0.70
▸ LPAR5 Q9H1C0 3/20 0.70
▸ LPAR2 Q9HBW0 3/20 0.70
▸ LPAR3 Q9UBY5 3/20 0.70
▸ ENPP2 Q13822 3/20 0.70
▸ LPAR6 P43657 2/20 0.70
▸ GPR55 Q9Y2T6 1/20 0.64
▸ CES2 O00748 1/20 0.61
▸ TRPV1 Q8NER1 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31442365 1.00 P2RY10 (0.72) P2RY10GPR174GPR34LPAR1LPAR4
SCHEMBL31442370 1.00 P2RY10 (0.72) P2RY10GPR174GPR34LPAR1LPAR4
SCHEMBL274812 1.00 P2RY10 (0.72) P2RY10GPR174GPR34LPAR1LPAR4
SCHEMBL14953735 1.00 P2RY10 (0.72) P2RY10GPR174GPR34LPAR1LPAR4
SCHEMBL31442542 1.00 P2RY10 (0.72) P2RY10GPR174GPR34LPAR1LPAR4
SCHEMBL21464913 1.00 P2RY10 (0.72) P2RY10GPR174GPR34LPAR1LPAR4
SCHEMBL14924219 1.00 P2RY10 (0.72) P2RY10GPR174GPR34LPAR1LPAR4
SCHEMBL15386593 1.00 P2RY10 (0.72) P2RY10GPR174GPR34LPAR1LPAR4
SCHEMBL14882712 1.00 P2RY10 (0.72) P2RY10GPR174GPR34LPAR1LPAR4
SCHEMBL13854646 1.00 P2RY10 (0.72) P2RY10GPR174GPR34LPAR1LPAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025123045-A1 PREDICTIVE AND DIAGNOSTIC SCREENING METHODS FOR ENDOMETRIAL CANCER ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2025-06-12 — — WO claimed
EP-4537111-A2 MULTI-OMICS ASSESSMENT Prognomiq Inc (US) 2025-04-16 — — EP claimed
CN-119534874-A Metabolic marker for auxiliary diagnosis of schizophrenia, construction method and application 驻马店市第二人民医院(驻马店市精神病医院) 2025-02-28 — — CN claimed
CN-118584095-A Use of intestinal contents as diarrhea markers 西北农林科技大学 2024-09-03 — — CN claimed
CN-118425358-A Use of lipid markers in detection of polycystic ovary syndrome 北京大学第三医院（北京大学第三临床医学院） 2024-08-02 — — CN claimed
CN-117554510-A Biomarker for detecting preeclampsia and application thereof 上海大学 2024-02-13 — — CN claimed
WO-2023240046-A2 MULTI-OMICS ASSESSMENT PrognomIQ, Inc. (US) 2023-12-14 — — WO claimed
CN-116660543-A Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof 中国人民解放军陆军军医大学第一附属医院 2023-08-29 — — CN claimed
US-20220354963-A1 EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF CODIAK BIOSCIENCES, INC. (US) 2022-11-10 — — US claimed
CN-114728078-A Extracellular vesicles linked to molecules and uses thereof 科迪亚克生物科学公司 2022-07-08 — — CN claimed
US-20220152559-A1 STABILIZED FILTRATION DEVICE RETEIN AB (SE) 2022-05-19 — — US claimed
CN-109946390-B Lung cancer diagnosis marker combination and application 上海市生物医药技术研究院 2022-05-06 — — CN claimed
US-12590309-B2 Reprogramming of lipid metabolism to inhibit T cell senescence and enhance tumor immunotherapy SAINT LOUIS UNIVERSITY (US) 2026-03-31 — — US disclosed
US-20260027147-A1 EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA LONZA SALES AG (CH) 2026-01-29 — — US disclosed
CN-121164482-A Metabolic marker for auxiliary diagnosis of schizophrenia, construction method and application 驻马店市第二人民医院(驻马店市精神病医院) 2025-12-19 — — CN disclosed
EP-4637812-A1 HEPATITIS B COMPOSITIONS GlaxoSmithKline Biologicals S.A. (BE) 2025-10-29 — — EP disclosed
US-8133736-B2 Methods for detecting or monitoring cancer using LPE as a marker UNIVERSITY OF SOUTH FLORIDA (US) 2012-03-13 — — US disclosed
US-8133736-B2 Methods for detecting or monitoring cancer using LPE as a marker UNIVERSITY OF SOUTH FLORIDA (US) 2012-03-13 — — US disclosed
US-20110059543-A1 METHODS FOR DETECTING OR MONITORING CANCER USING LPE AS A MARKER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-03-10 — — US disclosed
US-20110059543-A1 METHODS FOR DETECTING OR MONITORING CANCER USING LPE AS A MARKER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-03-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027147-A1 EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA CEBPZ, OSBP, DIS3 P2RY10 3776/4885GPR174 3317/4885GPR34 3199/4885
US-12590309-B2 Reprogramming of lipid metabolism to inhibit T cell senescence and enhance tumor immunotherapy PLA2G4A, PLA2G2A, PLA2G1B P2RY10 994/4885GPR174 3228/4885GPR34 4419/4885
US-20220354963-A1 EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF EXOSC5, EXOSC4, EXOSC10 P2RY10 4135/4885GPR174 4690/4885GPR34 4442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.